Bibliographic Details
| Title: |
Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient. |
| Authors: |
Cancela-Díez, Bárbara1 b.cancela.diez@gmail.com, Gómez-De Rueda, Félix2, Antolinos Pérez, María J3, Jiménez-Morales, Alberto1, López-Hidalgo, Javier L4 |
| Source: |
Journal of Oncology Pharmacy Practice. Jan2020, Vol. 26 Issue 1, p252-255. 4p. 1 Black and White Photograph, 1 Graph. |
| Subject Terms: |
*ANTINEOPLASTIC agents, *COLITIS, *IMMUNOTHERAPY, *LUNG tumors, *TREATMENT effectiveness, *ACUTE coronary syndrome, *DISEASE risk factors |
| Abstract: |
Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary syndrome, are poorly described. Herein, we report a possible acute coronary syndrome as immune-related adverse event in a lung cancer patient. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Oncology Pharmacy Practice is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
